The PPAR-α selective agonist WY14643 improves lupus nephritis via the downregulation of the RORγT/STAT3 signaling pathway in MRL/lpr mice
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2024.113787 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Haneen A Al-Mazroua und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Lupus Nephritis, Mice, Inbred MRL lpr, PPAR alpha. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 70 Literaturangaben. Gefördert von: King Saud University.
Abstract (Originalsprache)
Systemic lupus erythematosus (SLE) is a classic autoimmune disorder that mostly affects young women and involves various organs, such as the skin, joints, central nervous system, and kidneys. WY14643, a selective agonist of peroxisome proliferator-activated receptor-α, has previously shown anti-inflammatory effects in various disease models. However, its effects on lupus nephritis are yet to be explored. Therefore, the efficacy of WY14643 on renal biomarkers and lupus nephritis was assessed in MRL/lpr mice. Flow cytometry was used to examinethe effects of WY14643 on the expression of IL-17A, STAT3, RORγT, IL-21, IL-21R, IL-22, and TNF-α in splenic CD4+ T cells. We further investigated the impact of WY14643 on the mRNA expression of IL-17A, STAT3, RORγT, IL-21, IL-21R, IL-22, and TNF-α in kidney tissue via RT-PCR analysis. The administration of WY14643 effectively improved the symptoms of lupus nephritis in MRL/lpr mice. The administration of WY14643 decreased serum albumin, urine protein, serum creatinine, and blood urea nitrogen levels in MRL/lpr mice. WY14643 reduced the levels of inflammatory markers, including CD4+IL-17A+, CD4+STAT3+, CD4+RORγT+, CD4+IL-21+, CD4+IL-21R+, CD4+IL-22+, and CD4+TNF-α+, in the spleen cells of MRL/lpr mice. Additionally, we discovered that the administration of WY14643 resulted in the suppression of mRNA levels of IL-17A, STAT3, RORγT, IL-21, IL-22, and TNF-α. The current work shows that the suppression of inflammatory cells by WY14643 may effectively reduce autoimmune characteristics, such as renal inflammation, in lupus-prone MRL/lpr mice. Therefore, WY14643, being a specific PPAR-α agonist, shows significant potential as a novel therapeutic option for treatingnephritis associated with SLE, offering hope for future treatments in this challenging field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
- Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
- Department of Zoology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia.
- Department of Physiology, College of Medicine, King Saud University, Riyadh 11451, Saudi Arabia.
- Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia. Electronic address: fashaikh@ksu.edu.sa.
Förderung
- King Saud University
Zitieren
APA
Al-Mazroua, H. A., Nadeem, A., Attia, S. M., Bakheet, S. A., Ahmad, A., Ansari, M. A., Ibrahim, K. E., Alomar, H. A., Almutairi, M. M., Algarzae, N. K., Mahmoud, M. A., Hussein, M. H., Ahmed, O. M., & Ahmad, S. F. (2025). The PPAR-α selective agonist WY14643 improves lupus nephritis via the downregulation of the RORγT/STAT3 signaling pathway in MRL/lpr mice. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113787
Vancouver
Al-Mazroua HA, Nadeem A, Attia SM, Bakheet SA, Ahmad A, Ansari MA, et al. The PPAR-α selective agonist WY14643 improves lupus nephritis via the downregulation of the RORγT/STAT3 signaling pathway in MRL/lpr mice. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2024.113787
BibTeX
@article{AlMazroua2025,
author = {Al-Mazroua, Haneen A and Nadeem, Ahmed and Attia, Sabry M and Bakheet, Saleh A and Ahmad, Ajaz and Ansari, Mushtaq A and Ibrahim, Khalid E and Alomar, Hatun A and Almutairi, Mohammed M and Algarzae, Norah K and Mahmoud, Mohamed A and Hussein, Marwa H and Ahmed, Omer M and Ahmad, Sheikh F},
title = {The PPAR-α selective agonist WY14643 improves lupus nephritis via the downregulation of the RORγT/STAT3 signaling pathway in MRL/lpr mice},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2024.113787}
}
EUVIMED